Carbamazepine promotes liver regeneration and survival in mice

Tsukasa Kawaguchi[†], Takahiro Kodama[†], Hayato Hikita, Satoshi Tanaka, Minoru Shigekawa, Takatoshi Nawa, Satoshi Shimizu, Wei Li, Takuya Miyagi, Naoki Hiramatsu, Tomohide Tatsumi Tetsuo Takehara*

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan

Background & Aims: Carbamazepine (CBZ), a widely used anticonvulsant and mood stabilizer, activates multiple proliferative and pro-survival pathways. Here, we hypothesize that CBZ may promote hepatocellular proliferation and ameliorate liver regeneration.

Methods: C57BL6/J mice were orally administered CBZ or vehicle and underwent a 70% partial hepatectomy (PHx), 85% PHx or treatment with carbon tetrachloride (CCl₄). Liver regeneration was determined by liver to body weight ratio, hepatocyte proliferation markers, and activation of intracellular signalling pathways.

Results: Two to 5 days after the 70% PHx, the liver to body weight ratio was significantly higher in the CBZ-treated mice than in the vehicle-treated mice. CBZ treatment upregulated the number of proliferative hepatocytes following PHx or CCl₄ treatment, as assessed by intrahepatic Ki-67 staining, BrdU uptake, and PCNA protein expression. PHx surgery induced the expression of several cyclins and activated Akt/mTOR signalling pathways, all of which were enhanced by CBZ treatment. The administration of the mTOR inhibitor temsirolimus abrogated the hepato-proliferative effect of CBZ. CBZ treatment significantly improved the survival rate of the mice that underwent lethal 85% massive hepatectomy.

Conclusions: CBZ demonstrated a novel hepato-proliferative effect through the activation of the mTOR signalling pathway in hepatectomised mice. CBZ has the potential to be a therapeutic option for facilitating efficient liver regeneration in patients subjected to liver surgery.

© 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

These authors contributed equally to this work and share first authorship. Abbreviations: CBZ, carbamazepine; PHx, partial hepatectomy; PI-3K, phosphotidylinositol-3 kinase; MAPK, ras-mitogen-activated protein kinase; ERK, extracellular signal regulated kinase; DMSO, dimethyl sulfoxide; H&E, haematoxylin and eosin: IHC, immunohistochemistry: RT-PCR, reverse transcription PCR: INK, c-jun N-terminal kinase; CCl₄, carbon tetrachloride; NPC, non-parenchymal cells; HGF, hepatocyte growth factor.



Introduction

Hepatocyte proliferation is critically important in liver regeneration after surgical resection or living donor transplantation. It involves the recovery from loss of volume and impaired liver function [1–3]. If this fundamental proliferative ability is not sufficient to compensate for the resected liver, postoperative liver failure will occur, which is a serious complication and remains an important clinical problem [4,5]. To overcome this issue, therapeutic methods that support liver regeneration must be explored. However, few treatment options are capable of enhancing liver regeneration in a clinical setting, despite widespread interest and numerous trials [6,7]. Carbamazepine (CBZ) is FDA-approved and widely used as an anticonvulsant or a mood stabiliser in clinical settings [8,9]. Mood stabilisers have been shown to exert prosurvival and cytoprotective effects on neuronal cells through the activation of intracellular signalling pathways that involve the phosphotidylinositol-3 kinase (PI-3K)-Akt pathway and the Ras-mitogen-activated protein kinase (MAPK) cascade [10-12]. In fact, CBZ induces a rapid and prolonged phosphorylation of extracellular signal regulated kinase (ERK) in human neuroblastoma cells [13]. In addition to the close relationship of CBZ to prosurvival signalling, a recent report revealed the therapeutic potential of CBZ in treating liver fibrosis caused by α 1-antitrypsin deficiency, one of the chronic liver diseases leading to cirrhosis and liver failure [14]. These findings fascinated us enough to encourage the evaluation of the favourable effect of CBZ on liver regeneration after surgical resection. In the present study, we identified a novel hepatoproliferative effect of CBZ on hepatectomised mice that is mediated through the activation of the mTOR pathway. This effect could partially protect the mice against the high lethality associated with massive liver resection. These results imply the therapeutic potential of CBZ to support liver regeneration in patients who are subjected to liver resection or living donor transplantation.

Materials and methods

Mice

Six- to eight-week-old male C57BL/6J mice were purchased from Charles River Laboratories Japan (Tokyo). The mice were maintained in a specific pathogen-free facility with a 12-hour-dark/12-hour-light cycle and received humane treatment. All animal-related procedures were approved by the Animal Care and Use committee of Osaka University Medical School.



Keywords: Carbamazepine; Liver regeneration; Hepatocyte proliferation; Akt; mTOR

Received 25 December 2012; received in revised form 3 July 2013; accepted 5 July 2013; available online 18 July 2013

^{*} Corresponding author. Address: Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. Tel.: +81 6 6879 3621; fax: +81 6 6879 3629. E-mail address: takehara@gh.med.osaka-u.ac.jp (T. Takehara).

Research Article

Surgery and materials

The mice were anesthetised with inhaled isoflurane and subjected to sham operation or 70% partial hepatectomy (PHx) as previously described (n >3 for each group and time point) [15]. Then, the mice were euthanized at indicated time points after surgery. The 85% PHx surgical procedure was identical to 70% PHx but with the additional resection of the right lower and caudate lobes [16]. Carbamazepine (CBZ) was purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in a stock solution of 50 mg/ml dimethyl sulfoxide (DMSO). The mice were orally administered 250 mg/kg of CBZ or an equivalent volume of DMSO 2 h before surgery. The CBZ dosage was determined based on a previous *in vivo* study [14]. Temsirolimus was purchased from Sigma-Aldrich and dissolved in a stock solution of 20 mg/ml DMSO. The mice were injected intraperitoneally with 5 mg/kg of temsirolimus dosage was determined based on a previous *in vivo* study reporting its inhibitory effects on mTOR [17].

Blood tests

To measure serum AST and ALT levels, blood was collected from the inferior vena cava of mice and centrifuged at 10,000g at room temperature for 15 min. Serum AST and ALT levels were measured by a standard method at the Oriental Kobo Life Science Laboratory (Nagahama, Japan).

Histological analyses

The dissected livers were fixed in formalin and embedded in paraffin. The sections were stained with haematoxylin and eosin (H&E). To assess hepatocyte proliferation, the sections were further processed for immunohistochemistry (IHC) with anti-Ki-67 antibody (Sigma-Aldrich) and anti-PCNA antibody (Cell Signaling Technology, Beverly MA). For IHC, antigen retrieval was performed by steaming for 20 min in $1 \times$ Target Retrieval Solution (pH 6.0) (DAKO, Glostrup, Denmark). The quenching of the endogenous peroxidase was accomplished with a 10-min incubation in 3% hydrogen peroxide in methanol. Sections were stained using the immunoperoxidase technique and counterstained with haematoxylin. We also stained liver sections for nuclear BrdU incorporation as previously described [18].

Western blot analysis

A piece of frozen liver tissue was lysed in lysis buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 1 × protease inhibitor cocktail [Nacalai Tesque, Kyoto Japan], 1 × phosphatase inhibitor cocktail [Nacalai Tesque], phosphatebuffered saline, pH7.4). The homogenates were purified by centrifugation at 10,000g at 4 °C for 15 min. The protein concentrations were determined using a bicinchoninic acid protein assay (Thermo Scientific, Rockford, IL). Equal amounts of protein extract were electrophoretically separated by SDS polyacrylamide gels and transferred onto a polyvinylidene fluoride membrane. For immunodetection, the following antibodies were used: anti-cyclinE1, anti-Akt, anti-phospho Akt (Thr 308), anti-phospho Akt (Ser 473), anti-mTOR, anti-phospho mTOR (Ser 2448), anti-S6K, anti-phospho S6K (Thr 389), anti-4EBP1, anti-phospho-4EBP1 (Thr 37/46), anti-ERK, and anti-phospho ERK (Thr 202/Tyr 204), anti-JNK, antiphospho JNK (Thr 183/Tyr 185) (Cell Signaling Technology), anti-cyclinA (Santa Cruz Biotechnology Inc., Santa Cruz, CA), PCNA and β -actin (Sigma-Aldrich).

Real-time quantitative PCR

Total RNA isolated from liver tissues using an RNeasy Mini Kit (QIAGEN) was reverse transcribed and subjected to real-time reverse transcription PCR (RT-PCR) as previously described [18]. The mRNA expression levels of the specific genes were quantified using TaqMan Gene Expression Assays (Applied Biosystems) as follows: murine *ccna2* (assay ID:Mm00438063_m1), murine *ccne2* (assay ID:Mm00438077_m1), murine *hgf* (assay ID:Mm01135193_m1), murine *il6* (assay ID:Mm00446190_m1) and murine *actb* (assay ID:Mm00607939_s1). The transcript levels are presented as fold change relative to the controls.

Statistics

Data are expressed as mean \pm SD. Statistical analyses between two groups were performed by an unpaired Student's *t* test unless otherwise indicated. Multiple comparisons were performed by a one-way ANOVA, and differences in the mean values among groups were examined by a Fischer *post hoc* correction. *p* values less than 0.05 were considered to be statistically significant.

CBZ promotes liver regeneration after PHx

To test whether CBZ has any effect on liver regeneration, male C57BL6/J mice were orally administered CBZ or vehicle and underwent 70% PHx. The PHx procedure allows for a well-established liver regeneration model in which the liver recovers full volume after surgery. In the sham-operated mice, no difference was found in liver to body weight ratio at 48 h after drug administration between the CBZtreated and vehicle-treated groups (Supplementary Fig. 1). In the hepatectomised mice, the ratio was significantly higher in the CBZtreated group than in the vehicle-treated group (Supplementary Fig. 1). We then examined the liver to body weight ratio at several time points after surgery with or without one-time oral CBZ administration. After PHx, the liver to body weight ratio was rapidly recovered in the CBZ-treated mice and was significantly higher than in the vehicle-treated mice at 2, 3 and 5 days after PHx (Fig. 1A). The liver to body weight ratio reached similar levels by 14 days after surgery in both groups (Fig. 1A). These findings demonstrate that CBZ promoted liver regeneration after PHx in mice.

CBZ enhances hepatocyte proliferation after PHx

During liver regeneration, hepatocyte proliferation is critically important in compensating for the lost liver mass and liver function recovery. To determine whether CBZ affects hepatocyte proliferation in the hepatectomised mice, hepatocyte DNA synthesis was assessed by immunohistochemical staining of liver sections with Ki-67 and BrdU-two principal markers of DNA replication. We first confirmed that there was no difference in liver injury after PHx in the CBZ- or vehicle-treated mice, by evaluation of serum AST and ALT levels (Fig. 1B and C). H&E staining also revealed that there was no inflammatory cell infiltration or necrosis in the livers of either group (Fig. 1D). The number of Ki-67 positive cells increased to a peak at 48 h after PHx in both groups (Fig. 1E and F), but the peak value was significantly higher in the CBZ-treated livers (Fig. 1E and F). Similarly, the number of BrdU-positive nuclei was also significantly higher in CBZ-treated mice than in vehicletreated mice at 36 h after PHx (Fig. 1G and H). Western blotting indicated higher protein expression levels for proliferating nuclear antigen (PCNA), another well-known marker of DNA replication, in CBZ-treated livers at 48 h after PHx (Fig. 1I). These findings indicate that CBZ increased the number of proliferative hepatocytes after PHx in mice. We also observed the similar hepato-proliferative effect and amelioration of liver regeneration in hepatectomized mice even after repeated CBZ administration for 3 consecutive days (Supplementary Fig. 2A and B), which is a more clinically relevant regimen since CBZ requires multiple administrations to reach steady state levels [19]. To determine whether this favourable effect of CBZ is only observed in a resected liver, CBZ-treated mice were administered a single injection of carbon tetrachloride (CCl₄), which causes acute liver injury, and followed compensative liver regeneration [20]. CBZ treatment did not affect the liver damage but enhanced hepatocyte proliferation (Supplementary Fig. 3A-C) suggesting that the hepato-proliferative effect of CBZ may not be limited to the hepatectomised liver.

We then examined the gene expression of several cyclins, accelerators of cell cycle progression, which are important for hepatocyte proliferation in regenerating livers [21]. A real-time RT-PCR analysis revealed that the mRNA levels of *ccne2* and *ccna2* were significantly higher in CBZ-treated mice than in

Download English Version:

https://daneshyari.com/en/article/6103986

Download Persian Version:

https://daneshyari.com/article/6103986

Daneshyari.com